{"id":531,"date":"2014-05-13T08:11:22","date_gmt":"2014-05-13T12:11:22","guid":{"rendered":"http:\/\/blog.bmbs.org\/?p=531"},"modified":"2014-05-13T10:12:04","modified_gmt":"2014-05-13T14:12:04","slug":"inversion","status":"publish","type":"post","link":"https:\/\/blog.bmbs.org\/?p=531","title":{"rendered":"Inversion"},"content":{"rendered":"<p><em>Inversion (n):\u00a0 The process by which U.S. companies acquire foreign competitors and reincorporate abroad in low-tax countries.<\/em><\/p>\n<p>Example of inversion:\u00a0 Pfizer is trying to buy British rival AstraZeneca for about $106 billion.\u00a0 Pfizer plans to move its holding company to Britain from the United States so it can achieve a much lower tax rate and use cash that it has held abroad to avoid paying U.S. taxes.<\/p>\n<p>According to NYT reporter Andrew Ross Sorkin, &#8220;By reincorporating in Britain, Pfizer would most likely save about $200 million a year for each percentage point less it pays in taxes, according to Barclays. Pfizer paid a 27.4 percent rate in the United States; AstraZeneca paid about 21.3 percent in Britain. Those six percentage points could turn into an annual windfall of more than $1 billion. That\u2019s not all: It gives Pfizer a revenue-generating asset without having to repatriate any of its $57 billion cash hoard sitting overseas.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Inversion (n):\u00a0 The process by which U.S. companies acquire foreign competitors and reincorporate abroad in low-tax countries. Example of inversion:\u00a0 Pfizer is trying to buy British rival AstraZeneca for about $106 billion.\u00a0 Pfizer plans to move its holding company to &hellip; <a href=\"https:\/\/blog.bmbs.org\/?p=531\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/blog.bmbs.org\/index.php?rest_route=\/wp\/v2\/posts\/531"}],"collection":[{"href":"https:\/\/blog.bmbs.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.bmbs.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.bmbs.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.bmbs.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=531"}],"version-history":[{"count":2,"href":"https:\/\/blog.bmbs.org\/index.php?rest_route=\/wp\/v2\/posts\/531\/revisions"}],"predecessor-version":[{"id":533,"href":"https:\/\/blog.bmbs.org\/index.php?rest_route=\/wp\/v2\/posts\/531\/revisions\/533"}],"wp:attachment":[{"href":"https:\/\/blog.bmbs.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.bmbs.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.bmbs.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}